Related Experiment Videos
Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a
A Tichelli1, A Gratwohl, C Berger
1Department of Internal Medicine, Kantonsspital, Basel, Switzerland.
Abstract:
In an open prospective pilot trial, we tested the effect of recombinant interferon alpha-2 a (rIFN alpha-2 a) on thrombocytosis in myeloproliferative disorders (MPD). Since October 1986, 13 patients with MPD (4 with chronic granulocytic leukemia, 4 with polycythemia vera, 3 with essential thrombocythemia and 2 with myeloid metaplasia) were treated with rIFN alpha-2 a. Platelet counts decreased in all treated patients within 2 to 10 weeks from a median value of 1,050 x 10(9)/l (range 610-1,940 x 10(9)/l) to 340 x 10(9)/l (range 230-495 x 10(9)/l). The response was dose-dependent. In 11 patients we observed a simultaneous reduction of the white blood cell count. Six patients still continue the IFN alpha-2 a therapy. In 7 treatment was discontinued, because of chronic side effects in 3, and because of noncompliance in one. In these patients, thrombocytosis recurred after discontinuation of the therapy. These results show that rIFN alpha-2 a is effective in controlling thrombocytosis in MPD. However, the long-term benefit of interferon in these disorders remains to be established.
Insights
Recombinant interferon alpha-2 a (rIFN alpha-2 a) effectively reduced thrombocytosis in myeloproliferative disorders (MPD). Platelet counts normalized in all patients, though long-term benefits require further study.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myeloproliferative disorders (MPD) are a group of conditions characterized by the overproduction of blood cells.
- Thrombocytosis, a high platelet count, is a common feature of MPD and can increase the risk of blood clots.
- Effective treatments for thrombocytosis in MPD are crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of recombinant interferon alpha-2 a (rIFN alpha-2 a) in managing thrombocytosis in patients with MPD.
- To assess the dose-dependency and side effects of rIFN alpha-2 a therapy in this patient population.
Main Methods:
- An open prospective pilot trial involving 13 patients diagnosed with various MPDs.
- Patients received treatment with rIFN alpha-2 a, with platelet and white blood cell counts monitored.
- Treatment duration and reasons for discontinuation were recorded.
Main Results:
- All 13 patients experienced a significant decrease in platelet counts within 2-10 weeks of initiating rIFN alpha-2 a therapy.
- The reduction in platelet counts was dose-dependent.
- Eleven patients also showed a decrease in white blood cell counts. Thrombocytosis recurred upon discontinuation of therapy.
Conclusions:
- rIFN alpha-2 a demonstrates significant efficacy in controlling thrombocytosis associated with myeloproliferative disorders.
- While effective in the short term, the long-term clinical benefit and optimal use of interferon therapy in MPD require further investigation.